Synergistic Combinations for Neurodegenerative Disease Treatment

A novel approach integrating Type I PRMT inhibitors with distinct technologies like AI, IoT, blockchain, and new materials to create more effective systems for treating neurodegenerative diseases, such as ALS and FTD.

The original patent, 'Inhibition of dipeptide repeat proteins,' addressed the treatment of neurological disorders, including ALS and FTD, by inhibiting dipeptide repeat proteins using Type I PRMT inhibitors. However, the patent did not fully explore the potential of integrating these inhibitors with other technologies to create more powerful systems. The present inventive concept solves this problem by synergistically combining Type I PRMT inhibitors with AI, IoT, blockchain, and new materials to create novel systems for treating neurodegenerative diseases.

The inventive concept comprises various systems and methods that integrate Type I PRMT inhibitors with distinct technologies to create more effective treatments for neurodegenerative diseases. For instance, a system for treating neurodegenerative diseases may comprise a Type I PRMT inhibitor and a blockchain-based data storage unit for tracking patient responses. Another example is a method for identifying optimal dosages of a Type I PRMT inhibitor using machine learning algorithms and data from wearable IoT devices. Additionally, a composition of matter may comprise a Type I PRMT inhibitor and a nanoparticle-based delivery system, wherein the nanoparticle is functionalized with a targeting moiety for motor neurons. These synergistic combinations enable more targeted, efficient, and effective treatments for neurodegenerative diseases.

The novelty of the inventive concept lies in the synergistic combination of Type I PRMT inhibitors with distinct technologies, which creates new and non-obvious systems and methods for treating neurodegenerative diseases. The inventive step is the recognition of the potential benefits of integrating these technologies and the development of novel systems and methods that achieve these benefits.

Alternative embodiments of the inventive concept may include different types of inhibitors, such as Type II or Type III PRMT inhibitors, or the use of different AI or machine learning algorithms. Variations may also include the integration of additional technologies, such as gene editing or optogenetics, to create even more effective systems for treating neurodegenerative diseases.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of neurodegenerative disease treatment. The market for ALS and FTD treatments is substantial, and the integration of distinct technologies with Type I PRMT inhibitors is expected to create new opportunities for companies and researchers working in this space.